Women Supervised Under Professional Methadone Programs Show Comparable Pregnancy Outcomes to Non-Methadone Users [14L]

Holloman, Conisha; Oshodi, Temitope; Carlan, S. J.

doi:10.1097/01.aog.0000483423.08397.07

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Derakhshan et al also showed that low birth weight was more frequent in the opium-exposed neonates compared to the control group neonates (26). Holloman et al reported that the birth weight of neonates of mothers receiving MMT and mothers using other drugs was 3,037 and 2,747 g, respectively (22). Like our findings, Hayes et al (27) and Greig et al (28) revealed a reduced head circumference in neonates of mothers receiving MMT.…”

Section: Discussionsupporting

confidence: 81%

“…Besides, there was a significant difference between the prevalence of NICU admission in neonates of mothers using other drugs and the other two groups. Holloman et al reported that the prevalence of NICU admission in neonates was significantly higher in the mothers using other drugs (26%) compared to the MMT group (16%) (22). Gargari et al (6) and Vucinovic et al ( 31) also announced similar results.…”

Section: Discussionmentioning

confidence: 77%

“…Also, the prevalence of preterm birth was 15% in the MMT group and 53% in mothers using other drugs. There was a significant difference between gestational age and preterm delivery in these two groups (22), which indicates that MMT in pregnant women compared to abusing other drugs can increase the gestational age and decrease the risk of preterm birth (23,24).…”

Section: Discussionmentioning

confidence: 93%

“…In this study, a natural vaginal delivery was not different between the three groups. In the study by Holloman et al, there was also no significant difference between having a cesarean section in healthy and MMT groups (22); however, Richard et al showed a significant increase in cesarean section in drug-abusing mothers (29). These different findings can open a new horizon for further investigations.…”

Section: Discussionmentioning

confidence: 97%

See 3 more Smart Citations

Effect of Maternal Methadone Use on Neonatal Outcomes: Results of a Cohort Study

2021

View full text Add to dashboard Cite

Background: Substance abuse treatment is challenging in pregnancy, and methadone maintenance therapy (MMT) is a therapeutic choice. Methadone can cross the placenta and is poorly secreted in breast milk. Given these inconsistent findings of methadone effect on neonatal outcomes, this study was done to investigate the results in neonates of mothers treated with methadone in Mashhad. Methods: In this retrospective cohort study, mothers referring to two academic hospitals of Mashhad University of Medical Sciences were studied. Three groups were considered: MMT, other drug abusers, and healthy control. Maternal information, including demographic characteristics, fertility characteristics, and methadone treatment-related characteristics, and neonatal information, including demographic characteristics and neonatal outcomes, were assessed. Results: Overall, 122 pregnant women with a mean age of 29.14 ± 4.44 years were studied in three groups: control (n = 59), MMT (n = 32), and other drug abusers (n = 31). Baseline characteristics (mothers’ age, residence, chronic hypertension, preeclampsia, diabetes, heart disease, thyroid disease, and other diseases) were not different between the three groups. The highest history of miscarriage was seen in other drug abusers (35.5%) (P = 0.023). The mean weight, height, and head circumference of neonates in the control group were significantly higher than the methadone group (P < 0.001), and in the methadone group was higher than in the other drugs abusers (P < 0.001). The highest prevalence of malformations (16.1%) and hospitalization in the NICU (51.6%) was observed in infants of other drug abusers. After adjusting for confounding variables, the odds ratio (OR) of low-birth-weight infants was 13.7 in the methadone group and 1946 in the other drugs group compared to the healthy control group. The OR of neonates less than 50cm in height was 11.4 in the methadone group and 22.5 in the other drugs. Besides, the OR of neonates less than 35cm was 4.7 in the methadone group and 7.3 in other drugs. Conclusions: Although the neonates of mothers who used methadone had a higher rate of inappropriate intrauterine growth indices than healthy women, methadone consumption compared to other drugs had significantly reduced unacceptable outcomes in neonates. Increased gestational age and reduced preterm delivery risk were observed in methadone-treated mothers.

show abstract